Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1301 DDI Study with Midazolam and Atorvastatin in Healthy Participants
NCT07608705Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1301 in hyperlipidemia, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum observed plasma concentration at 18 days, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration at 18 days and 1 more. Started Jun 2026; status: completed.
02
Drugs
HRS-1301
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07608705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608705.